SEC Stock Data

Quick Answer Satellos Bioscience Inc. reported operating cash flow of -$23.60 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. Satellos Bioscience Inc. Operating … Read more

Quick Answer Satellos Bioscience Inc. reported total equity of $27.78 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. Satellos Bioscience Inc. Total Equity … Read more

Quick Answer Satellos Bioscience Inc. reported total liabilities of $4.11 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. Satellos Bioscience Inc. Total Liabilities … Read more

Quick Answer Satellos Bioscience Inc. reported total assets of $31.89 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. Satellos Bioscience Inc. Total Assets … Read more

Quick Answer Satellos Bioscience Inc. reported diluted eps of $-1.70 per share for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. Satellos Bioscience Inc. Diluted … Read more

Quick Answer Satellos Bioscience Inc. reported basic eps of $-1.70 per share for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. Satellos Bioscience Inc. Basic … Read more

Quick Answer Satellos Bioscience Inc. reported net income of -$24.87 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. Satellos Bioscience Inc. Net Income … Read more

Quick Answer Satellos Bioscience Inc. reported operating profit of -$26.46 million for fiscal year 2025 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. Satellos Bioscience Inc. Operating Profit … Read more

Quick Answer Satellos Bioscience Inc. reported operating profit of -$26.46 million for fiscal year 2025, reported under IFRS on Form 20-F. Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. Satellos Bioscience … Read more

Quick Answer MoneyHero Ltd reported operating cash flow of -$24.89 million for fiscal year 2024 (IFRS, Form 20-F). Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted. MoneyHero Ltd Operating Cash Flow … Read more